SAB Biotherapeutics, Inc.
SABS· Nasdaq
10-K due Mar 26 – Apr 5
No earnings release is on file for this company, so the day is the 10-K’s, projected from its last 6 filings.
Up after 4 of 12, down after 8.
SAB Biotherapeutics, Inc. · CIK 1833214 · Engraved from SEC EDGAR
Based on 6 prior 10-K filings.
The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: −15.3% after Q3 2024.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.